News & Events

Results of Operations and Financial Condition. On May 6, 2026, Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended March 31, 2026. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 17, 2026, Cencora, Inc. (the “Company”) announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer of the Company effective June 30, 2026. Mr. Cleary’s decision to retire from his position was not the result of a disagreement on any matter related to the Company’s operations, policies or practices.

Entry into a Material Definitive Agreement. On February 13, 2026, Cencora, Inc. (the “Company”) completed the sale of $3.0 billion aggregate principal amount of the Company’s Senior Notes as follows: $500,000,000 aggregate principal amount of the Company’s 3.950% Senior Notes due 2029 (the “2029 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2030 (the “2030 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.600% Senior Notes due 2033…

Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Other Events. On February 10, 2026, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”), by and among the Company, Citigroup Global Markets Inc., J.P. Morgan Securities LLC, BofA Securities, Inc. and Wells Fargo Securities, LLC on behalf of themselves and as representatives of the several underwriters named therein (the “Underwriters”). The Underwriting Agreement provides for the issuance and sale by the Company, and the purchase by the Underwriters, of the Notes…

Regulation FD Disclosure. On February 10, 2026, Cencora, Inc. (the “Company” or “Cencora”) issued a news release announcing that it priced $500,000,000 aggregate principal amount of the Company’s 3.950% Senior Notes due 2029 (the “2029 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2030 (the “2030 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.600% Senior Notes due 2033 (the “2033 Notes”), $1,000,000,000 aggregate principal amoun…

Other Events. Cencora, Inc. (the “Company”) is filing this Current Report on Form 8-K (this “Form 8-K”) to reflect a revision to the presentation of its financial information as set forth in its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (the “2025 Form 10-K”), as filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, to give effect to a change in its segment reporting. As previously disclosed, the Company undertook a strategic review of i…

Results of Operations and Financial Condition. On February 4, 2026 Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended December 31, 2025. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under

Regulation FD Disclosure. On February 2, 2026, the Company acquired the majority of the outstanding equity interests that it did not previously own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology for a total cash consideration of approximately $4.6 billion. OneOncology’s affiliated practices and management retained a minority interest in OneOncology. The Company funded the transaction through new debt financing. OneOncolo…

Regulation FD Disclosure. Executives of Cencora, Inc. (the “Company”) will be presenting at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025, at 8:40 a.m. ET. During this event, the Company’s executives will provide updates regarding certain performance expectations and recent business developments, including the following update to its fiscal year 2025 financial guidance: · Adjusted diluted earnings per share (EPS) for fiscal 2025 is now expected to be in the range…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 22, 2025, two members of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), Richard W. Gochnauer and Kathleen W. Hyle, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 6, 2025 (the “Annual Meeting”). Mr. Gochnauer and Ms. Hyle each indi…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 30, 2024, Gina K. Clark, Executive Vice President and Chief Communications & Administrative Officer of Cencora, Inc. (the “Company”), informed the Company that she intends to retire from her position, effective September 30, 2024. Ms. Clark’s decision to retire from her position was not the result of any disagreements with the Company’s ma…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 12, 2024, Henry W. McGee, a member of the Board of Directors (the “Board”) of Cencora, Inc. (the “Company”), informed the Board of his intent to retire and not stand for re-election as a director when his term expires at the Company's 2024 Annual Meeting of Stockholders to be held on March 12, 2024 (the “2024 Annual Meeting”). Mr. McGee'…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 23, 2023, two members of the Board of Directors (the “Board”) of AmerisourceBergen Corporation (the “Company”), Jane E. Henney, M.D. and Michael J. Long, each informed the Company of their intent to retire as directors at the upcoming Annual Meeting of Stockholders to be held on March 9, 2023 (the “Annual Meeting”). Dr. Henney and Mr. Lo…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 9, 2022, the Committee approved an increase in compensation for Mr. Mauch in connection with his appointment as Executive Vice President and Chief Operating Officer of the Company. Mr. Mauch’s annual base salary for the fiscal year ending September 30, 2023 increased to $975,000 from his base salary of $850,000 for the fiscal year ended…

Other Events. On June 27, 2022, AmerisourceBergen Corporation (the “Company”) and two other national pharmaceutical distributors entered into an agreement with the State of Oklahoma to resolve opioid-related claims. Pursuant to the agreement, the three distributors will pay up to approximately $308 million, including attorneys’ fees and costs, to the State of Oklahoma and its participating subdivisions. This amount is consistent with Oklahoma’s allocation under the previously announced compre…

Other Events. On August 20, 2021, Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen Corporation (the "Company"), adopted a pre-arranged Rule 10b5-1 stock trading plan (the "10b5-1 plan"). Under the 10b5-1 plan, Mr. Collis may sell up to an aggregate of 329,345 of the Company’s common stock, including 283,345 shares to be acquired through the exercise of vested stock options which are scheduled to expire on November 11, 2022 and November 9, 2023. Shares may…